US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
CLAIM: The International Criminal Court issued an arrest warrant for Israeli Prime Minister Benjamin2024-05-21- Nantou County,TaiwanA Taiwanese couple decked out in a tux and gown embrace in front of a mountain o2024-05-21
Yemen's Houthis say they targeted Western ships
By Muhammad Al Gebaly, Hatem Maher and Tala Ramadan, for ReutersHouthi followers protest to condemn2024-05-21Chinese state media demands British Museum return 23,000 cultural relics
Your web browser is no longer supported. To improve your experience update it here2024-05-21Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
Hollywood star Shia LaBeouf has shocked onlookers after being spotted on the streets of Barry in Wal2024-05-21Officials advise softer is better when it comes to boot camps
Photo: RNZ / Samuel Rillstone2024-05-21
atest comment